Author Archives for Adeline Chauvigné

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article

Rédigé par Adeline Chauvigné, le 2016-06-17

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article

Rédigé par Adeline Chauvigné, le 2016-06-16

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article

InFlectis BioScience raises €6 million

InFlectis BioScience raises €6 million in a Series A round to perform clinical trial in humans. Nantes, France – June... View Article

Rédigé par Adeline Chauvigné, le 2016-06-15

InFlectis BioScience raises €6 million

InFlectis BioScience raises €6 million in a Series A round to perform clinical trial in humans. Nantes, France – June... View Article

OSE Pharma merge with Effimune to create OSE Immunotherapeutics

OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics Paris, Nantes, May 31, 2016 – OSE Pharma SA... View Article

Effimune, launch of an hepatocellular carcinoma study

OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program. Paris,... View Article

Rédigé par Adeline Chauvigné, le 2016-05-25

Effimune, launch of an hepatocellular carcinoma study

OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program. Paris,... View Article

BIND Therapeutics Announces Collaboration with Affilogic

BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor... View Article

Ipi Santé : new member

IPISANTE is developing a customized web collaborative tool, and is performing, for healthcare and wellness professionals, digital solutions which are... View Article

Rédigé par Adeline Chauvigné, le 2016-05-09

Ipi Santé : new member

IPISANTE is developing a customized web collaborative tool, and is performing, for healthcare and wellness professionals, digital solutions which are... View Article

UBO : new member

The University of Western Brittany (UBO) is focusing its activities in the marine areas, human and social sciences, health and... View Article

Rédigé par Adeline Chauvigné, le 2016-05-09

UBO : new member

The University of Western Brittany (UBO) is focusing its activities in the marine areas, human and social sciences, health and... View Article

Pierre Fabre : New member

Pierre Fabre is a private pharmaceutical and dermo-cosmetics group, founded in 1962, by Pierre Fabre. In 2015, its turnover exceeded... View Article

Rédigé par Adeline Chauvigné, le 2016-05-09

Pierre Fabre : New member

Pierre Fabre is a private pharmaceutical and dermo-cosmetics group, founded in 1962, by Pierre Fabre. In 2015, its turnover exceeded... View Article

Gene therapy, a strategic sector in the Pays de Loire region

“The CESTI IHU is a great tool to maintain and strengthen our competitiveness,” said Philippe Moullier, research director at INSERM... View Article

Rédigé par Adeline Chauvigné, le 2016-05-10

Gene therapy, a strategic sector in the Pays de Loire region

“The CESTI IHU is a great tool to maintain and strengthen our competitiveness,” said Philippe Moullier, research director at INSERM... View Article